Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|November 11, 2025

Maximizing Productivity and Scalability with Perfusion Technology

Perfusion-based upstream processing is redefining the production of biopharmaceuticals. By enabling continuous media exchange, perfusion systems maintain high cell density and cell health over longer periods, delivering higher productivity than traditional fed-batch approaches. The result is greater process efficiency, improved scalability, and broader access to affordable therapies. As Biopharma manufacturers face increasing pressure to accelerate timelines and reduce costs, perfusion technology offers a powerful path forward. This executive summary explores practical strategies for implementation, key process control insights, and real-world case studies demonstrating the advantages of perfusion-based production.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.